Results 191 to 200 of about 827,025 (271)

Computational strategies to address therapeutic resistance in estrogen receptor‐positive breast cancer: A narrative review of molecular docking, molecular dynamics simulations, and emerging therapeutic targets

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Computational drug discovery integrates molecular docking, molecular dynamics simulations, and translational clinical targeting to identify next‐generation therapeutics that overcome endocrine resistance in ER‐positive breast cancer. Combined with multi‐omics, artificial intelligence, and biomarker‐guided precision oncology, these approaches accelerate
Emmanuel Ifeanyi Obeagu, Yaregal Asres
wiley   +1 more source

PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. [PDF]

Target Oncol
Hamilton EP, Jeselsohn RM, Vahdat LT, Hurvitz SA.   +3 more
europepmc   +1 more source

Bioactive peptides in cancer and inflammation: Mechanisms, model systems and clinical translation

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Bioactive peptides (BAPs) derived from host, marine, insect, plant and synthetic sources share cationic, amphipathic structures adopting α‐helical, β‐sheet or cyclic conformations. These features underlie anti‐cancer effects, including membrane disruption, apoptosis and cell‐cycle arrest, anti‐metastatic activity, reduced invasion and migration, and ...
Najwa Doha, Richa Gill, Sergio Crovella, Haissam Abou‐Saleh, Sahar Isa Da'as   +4 more
wiley   +1 more source

SLV‐404, an anti‐RYK antibody–drug conjugate, is effective in Richter transformation patient‐derived xenografts

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract Richter transformation (RT), a highly aggressive lymphoma arising from a preexisting chronic lymphocytic leukemia, represents a major unmet clinical need. Recent data have shown that an antibody–drug conjugate (ADC) targeting the cell‐surface pseudokinase ROR1 is effective in RT patients.
Matilde Micillo, Beatrice Pirajno, Francesco Edoardo Vallone, Victor Navarro‐Tableros, Elisabetta Bolli, Valentina Griggio, Brian J. Lannutti, Katti A. Jessen, Tiziana Vaisitti, Silvia Deaglio   +9 more
wiley   +1 more source

DNA-Programmable Protein Degradation: Dynamic Control of Proteolysis-Targeting Chimera Activity via DNA Hybridization and Strand Displacement. [PDF]

JACS Au
Kashyap D, Haider S, Milne TA, Booth MJ.
europepmc   +1 more source

Targeting the PI3K/Akt Signaling Pathway: A Promising Therapeutic Strategy to Reduce Cancer Mortality and Overcome Chemoresistance

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims The phosphatidylinositol 3‐kinase (PI3K)/Akt signaling pathway is a central regulator of cellular properties that are essential for cancer progression, including cellular growth, survival, metabolism, and angiogenesis. Dysregulated PI3K/Akt signaling, often caused by genetic alterations in PIK3CA, loss of PTEN, or the ...
Md Mohiuddin
wiley   +1 more source

Understanding the Potential of Antibody‐Drug Conjugates Functionalized Engineered Exosomes in Hepatocellular Carcinoma Therapy: A Comprehensive Narrative Review

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Exosomes are naturally secreted nanovesicles with high biocompatibility, low immunogenicity, and the ability to traverse biological barriers, making them attractive theragnostic carriers. When engineered to present tumor‐specific antibodies and to deliver antibody‐drug conjugates (ADCs), they may enhance selective targeting of ...
Subham Sarkar, Avinaba Bose, Jenifer Rajak, Arup Kumar Mitra, Ajoy Kumer, Bikram Dhara   +5 more
wiley   +1 more source

Sigma‐1 Receptor‐Targeting Compounds Show Antiviral Activity Across Multiple Coronavirus Models

Journal of Medical Virology, Volume 98, Issue 10, October 2026.
ABSTRACT Over the past two decades, coronaviruses have caused three major public health crises, including the epidemics of SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2. Following the outbreak of SARS‐CoV‐2, several antiviral drugs have been approved for the treatment of COVID‐19.
Cuiling Zhang, Xingpeng Dong, Jiaying Liu, Minghua chen, Lisen Lin, Gaojie Song, Xianzhu Xia, Gaoxing Su, Xiao Li, Chao Shang   +9 more
wiley   +1 more source

Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders. [PDF]

ChemMedChem
Almodóvar-Rivera CM, Tandon I, Mudududdla R, Esguerra PN, Lucio-Acero K, Tang W.   +5 more
europepmc   +1 more source

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

MedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta, Ramakrishna Vadde, Ganji Purnachandra Nagaraju   +2 more
wiley   +1 more source